The week in industry: the first oral drug for secondary progressive MS gets FDA approval
This week: Celgene and Exscientia enter partnership to accelerate drug discovery using artificial intelligence, Cardiff University launches new institute to develop new generation of therapeutics and AbbVie’s SKYRIZI™ gains its first approval in the Japanese market.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>